Nephrogenic Systemic Fibrosis

Common Name(s)

Nephrogenic Systemic Fibrosis

Nephrogenic fibrosing dermopathy (NFD) is a condition of unknown cause that affects different parts of the body, particularly the skin. Symptoms of the condition may include progressive swelling and tightening of the skin, sometimes resulting in contractures, and pruritis (itching).  The skin findings are similar to those seen in patients with scleroderma.  NFD was first described in 1997.  To date, NFD has only been reported in patients with kidney disease. 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Nephrogenic Systemic Fibrosis" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Nephrogenic Systemic Fibrosis" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Nephrogenic Systemic Fibrosis" returned 58 free, full-text research articles on human participants. First 3 results:

Erythema nodosum masking nephrogenic systemic fibrosis as initial skin manifestation.
 

Author(s): Kar Wah Fuah, Christopher Thiam Seong Lim

Journal:

 

Nephrogenic systemic fibrosis (NSF) is a complication of the gadolinium-based contrast agent used in imaging studies. It is typically characterised by hard, erythematous and indurated skin plaques with surrounding subcutaneous oedema. Distinct papules and subcutaneous nodules can ...

Last Updated: 31 Dec 1969

Go To URL
Nephrogenic systemic fibrosis: fibrotic plaques and contracture following exposure to gadolinium-based contrast media.
 

Author(s): Alice He, Shawn G Kwatra, John G Zampella, Manisha J Loss

Journal:

 

Last Updated: 31 Dec 1969

Go To URL
Evidence Suggesting a Role of Iron in a Mouse Model of Nephrogenic Systemic Fibrosis.
 

Author(s): Chhanda Bose, Judit K Megyesi, Sudhir V Shah, Kim M Hiatt, Kimberly A Hall, Oleg Karaduta, Sundararaman Swaminathan

Journal:

 

Nephrogenic systemic fibrosis is associated with gadolinium contrast exposure in patients with reduced kidney function and carries high morbidity and mortality. We have previously demonstrated that gadolinium contrast agents induce in vivo systemic iron mobilization and in vitro differentiation ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Nephrogenic Systemic Fibrosis" returned 25 free, full-text review articles on human participants. First 3 results:

[Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].
 

Author(s): Cristian U Varela, Juan Carlos Prieto-Rayo

Journal: Rev Med Chil. 2014 Dec;142(12):1565-74.

 

Nephrogenic systemic fibrosis (NSF) is a severe iatrogenic disease that affect patients with impaired renal function exposed to gadolinium-based contrast agents. Clinically, symptoms develop within days or weeks after the exposure and mimic a scleromyxedema. The causal relationship ...

Last Updated: 31 Dec 1969

Go To URL
Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media.
 

Author(s): Ana Canga, Maria Kislikova, María Martínez-Gálvez, Mercedes Arias, Patricia Fraga-Rivas, Cecilio Poyatos, Angel L M de Francisco

Journal: Nefrologia. 2014 ;34(4):428-38.

 

Nephrogenic systemic fibrosis is a fibrosing disorder that affects patients with impaired renal function and is associated with the administration of gadolinium-based contrast media used in MRI. Despite being in a group of drugs that were considered safe, report about this potentially ...

Last Updated: 31 Dec 1969

Go To URL
Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
 

Author(s): J T Heverhagen, G A Krombach, E Gizewski

Journal: Rofo. 2014 Jul;186(7):661-9.

 

Nephrogenic systemic fibrosis (NSF) is a serious, sometimes fatal disease. Findings in recent years have shown that a causal association between gadolinium containing contrast media and NSF is most likely. Therefore, the regulatory authorities have issued guidelines on the use of ...

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

There are currently no open clinical trials for this condition.